Not just research tools—proteasome inhibitors offer therapeutic promise

This publication has 15 references indexed in Scilit:

• Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model
  Journal of Clinical Investigation, 2002
• Proteasome inhibition in cancer: Development of PS-341
  Seminars in Oncology, 2001
• NF-κB signaling pathways in mammalian and insect innate immunity
  Genes & Development, 2001
• The 26S Proteasome: A Molecular Machine Designed for Controlled Proteolysis
  Annual Review of Biochemistry, 1999
• DEGRADATION OF CELL PROTEINS AND THE GENERATION OF MHC CLASS I-PRESENTED PEPTIDES
  Annual Review of Immunology, 1999
• THE UBIQUITIN SYSTEM
  Annual Review of Biochemistry, 1998
• Nuclear Factor-κB — A Pivotal Transcription Factor in Chronic Inflammatory Diseases
  New England Journal of Medicine, 1997
• Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules
  Cell, 1994
• The ubiquitinproteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB
  Cell, 1994
• A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes.
  Proceedings of the National Academy of Sciences, 1977